Trial Profile

Assessment of the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Volunteers

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV 903 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

20 Sep 2024 Planned End Date changed from 10 Dec 2023 to 31 Jan 2025.
20 Sep 2024 Planned primary completion date changed from 10 Dec 2023 to 31 Jan 2025.
20 Sep 2024 Planned initiation date changed from 5 Oct 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com